ContraVir Pharmaceuticals, Inc. Announces Pricing of $15.6 Million Public Offering
June 18, 2019 08:45 ET
|
ContraVir Pharmaceuticals Inc.
EDISON, N.J., June 18, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (“ContraVir,” the “Company,” “we,” “our” or “us”) (NASDAQ:CTRV), a biopharmaceutical company focused on the...
Compelling Positive Results Reported from Human Liver Experiments with ContraVir Pharmaceuticals’ NASH Drug Candidate
June 17, 2019 08:00 ET
|
ContraVir Pharmaceuticals Inc.
EDISON, N.J., June 17, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
ContraVir Pharmaceuticals Announces Publication of CRV431 Data from Experimental Model of Hepatitis B
June 11, 2019 08:30 ET
|
ContraVir Pharmaceuticals Inc.
EDISON, N.J., June 11, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
ContraVir Pharmaceuticals Sets the Stage for CRV431 Development in NASH with Positive Results from Second Model of Liver Fibrosis
June 06, 2019 08:00 ET
|
ContraVir Pharmaceuticals Inc.
EDISON, N.J., June 06, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
ContraVir Pharmaceuticals, Inc. Announces Reverse Stock Split
May 31, 2019 08:00 ET
|
ContraVir Pharmaceuticals Inc.
EDISON, N.J., May 31, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
ContraVir Pharmaceuticals Receives Positive Nasdaq Listing Decision
May 06, 2019 08:00 ET
|
ContraVir Pharmaceuticals Inc.
EDISON, N.J., May 06, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
ContraVir Pharmaceuticals to Present at the 2019 ThinkEquity Conference
April 29, 2019 08:30 ET
|
ContraVir Pharmaceuticals Inc.
EDISON, N.J., April 29, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
ContraVir Pharmaceuticals, Inc. Announces Pricing of $2.14 Million Public Offering
April 25, 2019 09:02 ET
|
ContraVir Pharmaceuticals Inc.
EDISON, N.J., April 25, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (“ContraVir,” the “Company,” “we,” “our” or “us”) (NASDAQ:CTRV), a biopharmaceutical company focused on the...
ContraVir Pharmaceuticals to Present CRV431 Phase 1 Data at the International Liver Congress™
April 11, 2019 08:00 ET
|
ContraVir Pharmaceuticals Inc.
EDISON, N.J., April 11, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
ContraVir Pharmaceuticals Announces Panel Participation at 31st Annual ROTH Conference
March 04, 2019 14:01 ET
|
ContraVir Pharmaceuticals Inc.
EDISON, N.J., March 04, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for...